Person who experienced the adverse event (patient)
Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
126560491 | 12656049 | 1 | I | 20160325 | 20160816 | 20160816 | PER | US-ROCHE-1732842 | ROCHE | 0.00 | F | Y | 0.00000 | 20160816 | CN | US | US |
Drug(s) used by person
Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
126560491 | 12656049 | 1 | PS | PEGASYS | PEGINTERFERON ALFA-2A | 1 | Subcutaneous | UNKNOWN | 103964 | 180 | UG | /wk | |||||||
126560491 | 12656049 | 2 | C | NAPROXEN. | NAPROXEN | 1 | Unknown | 0 | |||||||||||
126560491 | 12656049 | 3 | C | LASIX | FUROSEMIDE | 1 | 0 | ||||||||||||
126560491 | 12656049 | 4 | C | SPIRONOLACTONE. | SPIRONOLACTONE | 1 | 0 | ||||||||||||
126560491 | 12656049 | 5 | C | ADVIL | IBUPROFEN | 1 | 0 | ||||||||||||
126560491 | 12656049 | 6 | C | VITAMIN B12 | CYANOCOBALAMIN | 1 | 0 |
Indications of drugs used
Event ID | CASEID | INDI DRUG SEQ | INDI PT |
---|---|---|---|
126560491 | 12656049 | 1 | Hepatitis C |
Outcome of event
no results found |
Reactions reported
Event ID | CASEID | DRUG REC ACT | PT |
---|---|---|---|
126560491 | 12656049 | Fatigue | |
126560491 | 12656049 | Headache | |
126560491 | 12656049 | Myalgia | |
126560491 | 12656049 | Pyrexia |
Reporting Sources (this data is often not reported and may therefore be missing here)
no results found |
Therapies reported
Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
---|---|---|---|---|---|---|
126560491 | 12656049 | 1 | 20160302 | 0 |